Partial Lipodystrophy
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
AP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Amryt PharmaMetreleptin
Amryt Pharmametreleptin
Clinical Trials (2)
Total enrollment: 81 patients across 2 trials
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Start: Feb 2024Est. completion: Feb 202812 patients
Phase 4Recruiting
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Start: Dec 2021Est. completion: Oct 202669 patients
Phase 3Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 81 patients
1 companies competing in this space